REMARKS

In response to the Restriction Requirement mailed June 30, 2004, Applicants elect Group II, claims 5-14, 30 and 33 drawn to isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30 wherein the nucleic acid sequence may be selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, and 29, variants, fragments, and complements thereof; vectors, cells, pharmaceutical compositions, a kit comprising the pharmaceutical composition; classified in class 435, subclass 69.1, 320.1, 253.3, class 536, subclass 23.1.

It was further requested that Applicants select an amino acid sequence from claim 5, and a nucleic acid sequence from claims 8 and 9. In response, Applicants elect the amino acid sequence set forth in SEQ ID NO: 18, and the nucleic acid sequence set forth in SEQ ID NO: 17.

Upon entry of this amendment, claims 5-9, 12-14, 30 and 33 will be pending. Claims 1-4, 15-29, 31-32, 34-41 have been withdrawn without prejudice or disclaimer as drawn to non-elected subject matter. Applicants reserve the right to pursue these claims in a later application. Elected claims 10 and 11 have been canceled. Claims 5, 8-12 have been amended. No new matter has been added.

CONCLUSION

On the basis of the foregoing amendments and remarks, applicants respectfully submit that this paper is fully responsive and that the pending claims are in condition for allowance. Such action is respectfully requested. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Dated: February 24, 2005

Respectfully submitted,

George Yahwak, Reg. No. 26,824

CuraGen Corporation 555 Long Wharf Drive

New Haven, CT 06511

Tel: (203) 974-6303